SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001140361-22-030215
Filing Date
2022-08-18
Accepted
2022-08-18 09:04:04
Documents
2
Group Members
CAMAC CAPITAL, LLCCAMAC PARTNERS, LLCERIC SHAHINIAN

Document Format Files

Seq Description Document Type Size
1 SC 13D/A brhc10041018_sc13da.htm SC 13D/A 141754
2 EXHIBIT 99.2 brhc10041018_ex99-2.htm EX-99.2 5179
  Complete submission text file 0001140361-22-030215.txt   148675
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-89959 | Film No.: 221176403
SIC: 2834 Pharmaceutical Preparations

Mailing Address CAMAC CAPITAL, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK NY 10022
Business Address CAMAC CAPITAL, LLC 350 PARK AVENUE, 13TH FLOOR NEW YORK NY 10022 914-629-8496
Camac Fund, LP (Filed by) CIK: 0001516478 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A